A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age
2022-06-28
عنوان الدراسة
A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age
داعم الدراسة
GSK
دواء الدراسة
Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612
رقم بروتوكول الدراسة
114858
حالة الدراسة
Rejected
موقع الدراسة
KFMC
مرحلة الدراسة
3b
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.